KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $170.1 million.

  • Vir Biotechnology's Cash & Equivalents rose 103.0% to $170.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.1 million, marking a year-over-year increase of 103.0%. This contributed to the annual value of $222.9 million for FY2024, which is 771.14% down from last year.
  • Vir Biotechnology's Cash & Equivalents amounted to $170.1 million in Q3 2025, which was up 103.0% from $211.1 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Cash & Equivalents high stood at $1.5 billion for Q2 2022, and its period low was $160.7 million during Q1 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $452.1 million (2023), whereas its average is $533.9 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 20958.45% in 2021, then plummeted by 8051.78% in 2024.
  • Quarter analysis of 5 years shows Vir Biotechnology's Cash & Equivalents stood at $347.8 million in 2021, then surged by 143.99% to $848.6 million in 2022, then plummeted by 71.53% to $241.6 million in 2023, then decreased by 7.71% to $222.9 million in 2024, then decreased by 23.71% to $170.1 million in 2025.
  • Its Cash & Equivalents stands at $170.1 million for Q3 2025, versus $211.1 million for Q2 2025 and $273.6 million for Q1 2025.